WHA77 individual statement on climate change and health
On 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 15.4, Climate change and health.
IFPMA commends the Resolution and the recognition of climate change as an urgent global challenge.
Innovative pharmaceutical companies are setting ambitious, science-aligned targets and investing to develop environmentally sustainable products, manufacturing processes, and supply chains, without compromising safety, quality, and efficacy for best patient outcomes.
Pharmaceutical operations are complex and highly regulated, thus collaboration between industry, governments, regulators, and health systems actors, including suppliers, is required. Likewise, the climate change and health nexus is a multi-faceted area demanding solid collaboration.
The ATACH initiative is an important platform for mobilizing the resources and expertise needed to address this crisis. As a formal member of ATACH, IFPMA looks forward to constructively engaging with its actors by leveraging its sector’s experience, such as science and partnerships.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
